Sun Pharma shares in focus following US launch of LEQSELVITM, settlement with Incyte Corporation
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
Shares of Sun Pharmaceutical Industries are expected to remain in focus on Tuesday, July 15, after the company announced two significant developments regarding its oral treatment for severe alopecia areata, LEQSELVITM (deuruxolitinib), in the United States.In a regulatory filing on Monday, Sun Pharma informed that it has entered into a settlement and license agreement with Incyte Corporation about the litigation surrounding LEQSELVITM.The litigation had been pending before the United States District Court for the District of New Jersey. Under the terms of the agreement, both Sun Pharma and Incyte will mutually release each other from all claims that were raised or could have been raised in the litigation.As part of the settlement terms, Incyte has granted Sun Pharma a limited, non-exclusive license, along with certain other related patents pertaining to oral deuruxolitinib for specific non-hematology-oncology indications, including alopecia areata, within the United States.In consideration for the settlement and the license granted, Sun Pharma will make an upfront payment to Incyte, along with ongoing royalty payments that will continue until the expiry of the relevant patents. The company clarified that the other specific terms of the agreement remain confidential.In parallel, Sun Pharma also announced the commercial launch of LEQSELVITM (deuruxolitinib) 8 mg tablets in the United States. According to the official announcement, the drug is now available nationwide for prescription to healthcare providers and patients suffering from severe alopecia areata, offering a new treatment option in this space.LEQSELVITM is indicated for the treatment of adult patients diagnosed with severe alopecia areata.Highlighting the importance of this launch, Sun Pharma stated that treatment options for patients living with severe alopecia areata in the U.S. remain limited, underscoring the need for therapies such as LEQSELVITM.The company further disclosed that the drug had demonstrated promising clinical trial results. Specifically, one-third of patients treated with LEQSELVITM regained almost all of their hair by Week 24 of treatment.Moreover, 3% of patients achieved 80% or more scalp coverage in as early as eight weeks.: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
9 hours ago
- Economic Times
Federal Bank Q1 Results: Standalone net profit falls 15% YoY to Rs 862 crore; NII up 2%
Federal Bank on Saturday reported a standalone net profit of Rs 861.75 crore, down 14.6% year-over-year compared to a profit of Rs 1,009.53 crore in the corresponding quarter of last year. ADVERTISEMENT The bank also posted a 2% increase YoY in net interest income (NII), which rose to Rs 2,336.83 crore in the June quarter from Rs 2,291.98 crore a year ago. Despite the drop in bottom line, the lender posted its highest-ever other income of Rs 1,113 crore, which was up 21.6% from the year-ago period. Total income for the quarter rose 7.6% year-on-year to Rs 7,799.61 crore. KVS Manian, Managing Director & CEO of the bank, said the quarter 'reaffirmed the strength of our diversified model.' He noted that 'even in a typically soft Q1, we saw momentum in key segments like commercial banking, credit cards, and gold loans.''Our mid-yielding engines are firing well too,' Manian said. 'We delivered a strong operating performance, with improving productivity. Fee income hit a record high, and CASA ratios continued to improve steadily.' ADVERTISEMENT The bank's total deposits grew 8.03% to Rs 2.87 lakh crore, while net advances increased by 9.24% to Rs 2.41 lakh crore. Within this, retail advances rose 15.6% to Rs 81,047 crore, commercial banking loans jumped 30.3% to Rs 25,028 crore, and corporate loans grew 4.5% to Rs 83,680 bank's CASA (current account and savings account) base expanded 12% YoY to Rs 87,236 crore. Net interest margin for the quarter stood at 2.94%, while annualised earnings per share came in at Rs 14.07. ADVERTISEMENT Asset quality remained stable, with gross non-performing assets (NPAs) at 1.91% and net NPAs at 0.48%. Provision coverage ratio (excluding technical write-offs) stood at 74.41%.Manian said that 'while credit costs were elevated this quarter, they were largely driven by slippages in the Agri and MFI portfolios.' He added, 'Based on current trends, we expect these slippages to moderate and stabilise going forward, leading to a normalisation in credit costs.' ADVERTISEMENT The lender's capital adequacy ratio for the June 2025 quarter stood at 16.03%, and net worth increased 12.2% YoY to Rs 33,994 crore. Return on assets (ROA) and return on equity (ROE) for the quarter stood at 1% and 10.3%, respectively. 'With macro tailwinds building and our strategic themes gaining traction, we're confident of accelerating growth in the second half while staying disciplined on risk and profitability,' Manian said. (You can now subscribe to our ETMarkets WhatsApp channel)
Economic Times
11 hours ago
- Economic Times
JSW Cement cuts IPO size to Rs 3,600 cr; public offer to open on August 7
Live Events (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel JSW Cement, part of Sajjan Jindal-promoted diversified JSW Group , is set to launch its truncated Rs 3,600-crore initial public offering (IPO) on August total size of the issue, however, is lower than the earlier proposed issue of up to Rs 4,000 crore, according to the latest RHP ..The IPO will open for public subscription on August 7 and closes on August 11, while the anchor investor bidding date would be August 6 for JSW Cement, according to the Red Herring Prospectus (RHP) filed on initial share sale comprises a fresh issue of equity shares worth Rs 1,600 crore and an Offer for Sale of shares worth up to Rs 2,000 crore by investor a part of the OFS, private equity giant Apollo Management , through its affiliate AP Asia Opportunistic Holdings Pte Ltd, will be offloading shares worth Rs 931.80 crore, Synergy Metals Investments Holding Ltd will sell shares worth Rs 938.50 crore, and State Bank of India ( SBI ) will divest shares valued at Rs 129.70 Metals Investments Holding is an arm of Synergy Metals and Mining Fund, a private equity fund set up by a former executive of steelmaker ArcelorMittal, Sudhir Maheshwari, in per draft papers, the company will utilise proceeds worth Rs 800 crore to part-finance a new integrated cement unit at Nagaur, Rajasthan, and Rs 520 crore on prepayment or repayment of outstanding borrowings availed by it. The rest would be used for general corporate Mumbai-based company had earlier planned to raise Rs 4,000 crore. At the time of filing papers, JSW Cement said it intended to raise Rs 2,000 crore from a fresh issue of equity shares and an offer for sale (OFS) of Rs 2,000 crore by investor the size of the fresh capital-raising has been cut by Rs 400 crore from the fresh issue, as per the latest August 2024, JSW Cement filed preliminary IPO papers with Sebi, and later in September, the regulator kept the company's proposed initial share-sale on hold. On January 6, this year, the regulator finally gave its observation to float the of March 31, 2025, JSW Cement's total borrowings stood at Rs 6,166.6 the financial front, the company's revenue from operations for FY25 stood at Rs 5,813.1 crore against Rs 6,028.10 crore in FY24, and Rs 5,836.72 crore in company reported a loss of Rs 163.77 crore in FY25. Its profit was Rs 62 crore in FY24 and Rs 104 crore in of March 31, 2025, JSW Cement had an installed grinding capacity of 20.60 million metric tonnes per annum (MMTPA).According to the CRISIL report, JSW Cement is India's largest manufacturer of ground granulated blast furnace slag (GGBS), an eco-friendly product produced entirely from blast furnace slag (a by-product of the steel manufacturing process), with a market share in terms of GGBS sales of 84 per cent in company presently operates manufacturing operations at units based at Vijayanagar in Karnataka, Nandyal in Andhra Pradesh, Salboni in West Bengal, Jajpur in Odisha and Dolvi in Cement through its subsidiary Shiva Cement operates a clinker unit in Odisha. Axis Capital Ltd , Citigroup Global Markets India Pvt Ltd, DAM Capital Advisors Ltd , Goldman Sachs (India) Securities Pvt Ltd, Jefferies India Pvt Ltd, Kotak Mahindra Capital Company Ltd and SBI Capital Markets Ltd are responsible for managing the company's IPO company's shares will be listed on the BSE and NSE. PTI
Economic Times
12 hours ago
- Economic Times
Tariff uncertainty to keep markets on edge; healthcare seen as safer bet: Rajesh Palviya
(What's moving Sensex and Nifty Track latest market news, stock tips, Budget 2025, Share Market on Budget 2025 and expert advice, on ETMarkets. Also, is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds .) Subscribe to ET Prime and read the Economic Times ePaper Sensex Today. Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price
